Opioids and Other Analgesics

  • Marc A. Schuckit
Part of the Critical Issues in Psychiatry book series (CIPS)


This chapter is concerned with those pain-killing drugs (analgesics) that are most likely to be misused, ranging from propoxyphene (Darvon) through the synthetic, opiatelike drugs to the major opiates, including morphine and heroin. The generalizations made here apply to almost all prescription painkillers with the exception of the newer prescription anti-inflammatory medications. The material is also relevant to the newer opioid drugs, including the mixed agonist-antagonist butorphanol (Stadol or Borphanol), which is similar to buprenorphene (Buprenex) and nalbuphene (Nubain), as well as fentanyl (Sublimaze).1–4 Many of these newer medications have not yet met the test of time to determine their actual propensity to develop adverse reactions, including physical dependence.5


Methadone Maintenance Opioid Withdrawal Heroin Addict Opioid Drug Narcotic Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jaffe, J. H. Opioid-related disorders. In H. I. Kaplan & B. J. Saddock (Eds.), Comprehensive textbook of psychiatry (6th ed.). Baltimore, MD: Williams & Wilkins, 1995.Google Scholar
  2. 2.
    Jaffe, J. H., Knapp, C. M., & Ciraulo, D. A. Opiates: Clinical aspects. In J. H. Lowinson, P. Ruiz, R. B. Mill-man, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 158–166.Google Scholar
  3. 3.
    Simon, E. J. Opiates: Neurobiology. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 148–158.Google Scholar
  4. 4.
    Reisine, T., & Pasternak, G. Opioid analgesics and antagonists. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 521–557.Google Scholar
  5. 5.
    Singh, R. A., Mattoo, S. K., Malhotra A., & Varma, V. K. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica 86:46–48, 1992.PubMedGoogle Scholar
  6. 6.
    Springer, A. Heroin control: A historial overview. European Addiction Research 2:177–184, 1996.Google Scholar
  7. 7.
    Gossop, M. Living with drugs (4th ed.). London: Wildwood House, 1996.Google Scholar
  8. 8.
    Cicero, T. J., Adams, E. H., Geller, A., et al. A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. Drug and Alcohol Dependence, in press.Google Scholar
  9. 9.
    Schuckit, M. A., & Segal, D. S. Opioid drug abuse and dependence. In A. S. Fauci, E. Braunwald, K. J. Isselbacher, et al. (Eds.), Harrison ’s principles of internal medicine (14th ed.). New York: McGraw-Hill, 1998, pp. 2508–2512.Google Scholar
  10. 10.
    Buchanan, J. F., & Brown, C. R. ‘Designer drugs,’ a problem in clinical toxicology. Medical Toxicology 3:1–17, 1988.PubMedGoogle Scholar
  11. 11.
    Nestler, E. J. Under siege: The brain on opiates. Neuron 16:897–900, 1996.PubMedGoogle Scholar
  12. 12.
    Koob, M., & Nestler, E. Neuroscience. In Committee on Opportunities in Drug Abuse Research, Pathways of Addiction. Washington, DC: National Academy Press, 1996.Google Scholar
  13. 13.
    Markou, A., Kosten, T. R., & Koob, G. F. Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18:135–174, 1998.PubMedGoogle Scholar
  14. 14.
    Matthes, H. W. D., Maldonado, R., Simonin, F., et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 383:819–823, 1996.PubMedGoogle Scholar
  15. 15.
    Dore, G. M., Niven, B. E., Hargreaves, G., & Caradoc-Davies, G. The naloxone eye-drop test for opioid dependence. Drug and Alcohol Review 18:207–211, 1999.Google Scholar
  16. 16.
    Tanda, G., Pontieri, F. E., & Di Chiara, G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science 276:2048–2049, 1997.PubMedGoogle Scholar
  17. 17.
    Schlaepfer, T. E., Strain, E. C., Greenberg, B. D., et al. Site of opioid action in the human brain: Mu and kappa agonists’ subjective and cerebral blood flow effects. American Journal of Psychiatry 155:4, 1998.Google Scholar
  18. 18.
    Morgan, J. P. Designer drugs. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 264–269.Google Scholar
  19. 19.
    Langston, J., Ballard, P., Tetrud, J., & Irwin, I. Chronic parkinsonism in humans due to a product of meperi-dine-analog synthesis. Science 219:9789–9790, 1983.Google Scholar
  20. 20.
    Schuckit, M. A. Science, medicine, and the future: Substance use disorders. British Medical Journal 314:1605–1608, 1997.PubMedGoogle Scholar
  21. 21.
    Schuckit, M. A. Educating yourself about alcohol and drugs. New York: Plenum Publishing Co., 1998.Google Scholar
  22. 22.
    American Psychiatric Association. The diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Press, 1994.Google Scholar
  23. 23.
    Stimmel, B. The socioeconomics of heroin dependence. New England Journal of Medicine 287:1275–1280, 1972.PubMedGoogle Scholar
  24. 24.
    Strang, J., Griffiths, P., & Gossop, M. Heroin in the United Kingdom: Different forms, different origins and the relationship to different routes of administration. Drug and Alcohol Review 16:329–337, 1997.PubMedGoogle Scholar
  25. 25.
    Strang, J., Griffiths, P., & Gossop, M. Heroin smoking by ‘chasing the dragon’: Origins and history. Addiction 92:673–683, 1997.PubMedGoogle Scholar
  26. 26.
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Household Survey on drug abuse: Population estimates 1997. Rockville, MD: U.S. Department of Health and Human Services, 1998.Google Scholar
  27. 27.
    Johnston, L. D., O’Malley, P. M., & Bachman, J. G. National survey results on drug use from the Monitoring the Future Study, 1975–1997, Vol. I, Secondary School Students. Rockville, MD: National Institute on Drug Abuse, U.S. Department of Health and Human Services, 1998.Google Scholar
  28. 28.
    Royo-Bordonada, M. A., Cid-Ruzafa, J., Martin-Moreno, J. M., & Guallar, E. Drug and alcohol use in Spain: Consumption habits, attitudes and opinions. Public Health 111:277–284, 1997.PubMedGoogle Scholar
  29. 29.
    Mora, M. E., Villatoro, J., & Rojas, E. Drug use among students in Mexico’s northern border states. In Department of Health and Human Services, Epidemiologic Trends in Drug Abuse. Washington, DC: U.S. Government Printing Office, 1996, pp. 367–375.Google Scholar
  30. 30.
    Rounsaville, B. J., & Kleber, H. D. Untreated opiate addicts. How do they differ from those seeking treatment? Archives of General Psychiatry 42:1072–1077, 1985.PubMedGoogle Scholar
  31. 31.
    Zinberg, N. E., & Jacobson, R. C. The natural history of “chipping.” American Journal of Psychiatry 133:37–40, 1976.PubMedGoogle Scholar
  32. 32.
    Crofts, N., Louie, R., Rosenthal, D., & Jolley, D. The first hit: Circumstances surrounding initiation into injecting. Addiction 91:1187–1196, 1996.PubMedGoogle Scholar
  33. 33.
    Caplovitz, D. The working addict. New York: The Graduate School and the University Center of the City University of New York, 1976.Google Scholar
  34. 34.
    Robins, L. N. Vietnam veterans’ rapid recovery from heroin addiction: A fluke or normal expectation? Addiction 88:1041–1054, 1993.PubMedGoogle Scholar
  35. 35.
    Hser, Y., Anglin, D., & Powers, K. A 24-year follow-up of California narcotic addicts. Archives of General Psychiatry 50:577–584, 1993.PubMedGoogle Scholar
  36. 36.
    Maddux, J., & Desmond, D. P. Heroin addicts and nonaddicted brothers. American Journal of Drug and Alcohol Abuse 10:237–248, 1984.PubMedGoogle Scholar
  37. 37.
    Halikas, J. A., Darvish, H. S., & Rimmer, J. D. The black addict. 1. Methodology, chronology of addiction, and overview of the population. American Journal of Drug and Alcohol Abuse 3:529–543, 1976.PubMedGoogle Scholar
  38. 38.
    Strang, J., Griffiths, P., Powis, B., & Gossop, M. First use of heroin: Changes in route of administration over time. British Medical Journal 304:1222–1223, 1992.PubMedGoogle Scholar
  39. 39.
    Myers, M. G., Stewart, D. G., & Brown, S. A. Progression from conduct disorder to antisocial personality disorder following treatment for adolescent substance abuse. American Journal of Psychiatry 155:479–485, 1998.PubMedGoogle Scholar
  40. 40.
    Hanlon, T. E., Nurco, D. N., Kinlock, T. W., & Duszynski, K. R. Trends in criminal activity and drug use over an addiction career. American Journal of Drug and Alcohol Abuse 16:223–238, 1990.PubMedGoogle Scholar
  41. 41.
    Langenauer, B. J., & Bowden, C. L. A follow-up study of narcotic addicts in the NARA program. American Journal of Psychiatry 128:41–46, 1971.PubMedGoogle Scholar
  42. 42.
    O’Brien, C. P., Woody, G. E., & McLellan, A. T. Long-term consequences of opiate dependence. New England Journal of Medicine 304:1098–1099, 1981.PubMedGoogle Scholar
  43. 43.
    Vaillant, G. E. A 20-year follow-up of New York narcotic addicts. Archives of General Psychiatry 29:237–241, 1973.PubMedGoogle Scholar
  44. 44.
    Hulse, G. K., English, D. R., Milne, E., & Holman, C. D. J. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 94:221–229, 1999.PubMedGoogle Scholar
  45. 45.
    Frischer, M., Goldberg, D., Rahman, M., & Berney, L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982–1994. Addiction 92:412–427, 1997.Google Scholar
  46. 46.
    McGregor, C., Darke, S., Ali, R., & Christie, P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: Circumstances and risk perceptions. Addiction 93:701–711, 1998.PubMedGoogle Scholar
  47. 47.
    Kosten, T. R., Rounsaville, B. J., & Kleber, H. D. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Archives of General Psychiatry 43:733–738, 1986.PubMedGoogle Scholar
  48. 48.
    Editorial. Alcohol and politics. Lancet 1:1358, 1987.Google Scholar
  49. 49.
    Lehman, W. E. K., Barrett, M. E., & Simpson, D. D. Alcohol use by heroin addicts 12 years after drug abuse treatment. Journal of Studies on Alcohol 51:233–244, 1990.PubMedGoogle Scholar
  50. 50.
    Anglin, M. D., Almog, I. J., Fisher, D. G., & Peters, K. R. Alcohol use by heroin addicts: Evidence for an inverse relationship. A study of methadone maintenance and drug-free treatment samples. American Journal of Drug and Alcohol Abuse 15:191–207, 1989.PubMedGoogle Scholar
  51. 51.
    Kandel, D. B., & Davies, M. High school students who use crack and other drugs. Archives of General Psychiatry 53:71–80, 1996.PubMedGoogle Scholar
  52. 52.
    Negus, S. S., Gatch, M. B., & Mello, N. K. Effects of mu opioid agonists alone and in combination with cocaine and D-amphetamine in rhesus monkeys trained to discriminate cocaine. Neuropsychopharmacology 18:325–338, 1998.PubMedGoogle Scholar
  53. 53.
    Mattoo, S. K., Basu, D., Sharma, A., et al. Abuse of codeine-containing cough syrups: A report from India. Addiction 92:1783–1787, 1997.PubMedGoogle Scholar
  54. 54.
    Lass, H. Most chronic patient misuse drugs, study shows. Hospital Tribune World Service 6:2, 1976.Google Scholar
  55. 55.
    McAuliffe, W. E., Rohman, M., Santangelo, S., et al. Psychoactive drug use among practicing physicians and medical students. New England Journal of Medicine 315:805–810, 1986.PubMedGoogle Scholar
  56. 56.
    Maddux, J. F., Hoppe, S. K., & Costello, R. M. Psychoactive substance use among medical students. American Journal of Psychiatry 143:187–191, 1986.PubMedGoogle Scholar
  57. 57.
    Brooke, D. Why do some doctors become addicted? Addiction 91:317–319, 1996.PubMedGoogle Scholar
  58. 58.
    Ashton, C. H., & Kamali, F. Personality, lifestyles, alcohol, and drug consumption in a sample of British medical students. Medical Education 29:187–192, 1995.PubMedGoogle Scholar
  59. 59.
    Chotkowski, L. A. Clubbing of the fingers in heroin addiction. New England Journal of Medicine 311:262, 1984.PubMedGoogle Scholar
  60. 60.
    Council on Scientific Affairs. Scientific issues in drug testing. Journal of the American Medical Association 257:3110–3114, 1987.Google Scholar
  61. 61.
    Hawks, R. L., & Chiang, C. N. (Eds.). Urine testing for drugs of abuse. Rockville, MD: National Institute on Drug Abuse, 1986.Google Scholar
  62. 62.
    Powis, B., Strang, J., Griffiths, P., et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction 94:471–478, 1999.PubMedGoogle Scholar
  63. 63.
    Tardiff, K., Markuz, P. M., Leon, A. C., et al. Accidental fatal drug overdoses in New York City: 1990–1992. American Journal of Alcohol Abuse 22:135–146, 1996.Google Scholar
  64. 64.
    Ruttenbar, A. J., & Luke, J. L. Heroin-related deaths: New epidemiologic insights. Science 226:14–20, 1984.Google Scholar
  65. 65.
    Gossop, M., & Strang, J. Rapid anaesthetic-antagonist detoxification of heroin addicts: What origins, evidence base, and clinical justification? British Journal of Intensive Care 7:66–69, 1997.Google Scholar
  66. 66.
    Beam, J., Gossop, M., & Strang, J. Rapid opiate detoxification treatments. Drug and Alcohol Review 18:75–81, 1999.Google Scholar
  67. 67.
    Chang, G., & Kosten, T. R. Detoxification. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 377–383.Google Scholar
  68. 68.
    Salloway, S., Southwick, S., & Sadowsky, M. Opiate withdrawal presenting as posttraumatic stress disorder. Hospital and Community Psychiatry 41:666–667, 1990.PubMedGoogle Scholar
  69. 69.
    Satel, S. L., Kosten, T. R., Schuckit, M. A., & Fischman, M. W. Should protracted withdrawal from drugs be included in DSM-IV? American Journal of Psychiatry 150:695–704, 1993.PubMedGoogle Scholar
  70. 70.
    Desland, M., & Batey, R. High retention rates within a prospective study of heroin users. British Journal of Addiction 86:859–865, 1991.PubMedGoogle Scholar
  71. 71.
    Loimer, N., Linzmayer, L., Schmid, R., & Grünberger, J. Similar efficacy of abrupt and gradual opiate detoxification. American Journal of Drug and Alcohol Abuse 17:307–312, 1991.PubMedGoogle Scholar
  72. 72.
    Fishbain, D. A. Drug detoxification protocols. In C. D. Tollison & R. Kunkel (Eds.), Headaches. Philadelphia: Williams & Wilkins, 1993, pp. 327–346.Google Scholar
  73. 73.
    Fishbain, D. A., Rosomoff, H. L., Cutler, R., & Rosomoff, R. S. Opiate detoxification protocols. Annals of Clinical Psychiatry 5:53–65, 1993.PubMedGoogle Scholar
  74. 74.
    Merrill, J., & Marshall, R. Opioid detoxification using naloxone. Drug and Alcohol Review 16:3–6, 1997.PubMedGoogle Scholar
  75. 75.
    Shapira, J. Drug abuse: A guide for the clinician. New York: American Elsevier, 1975.Google Scholar
  76. 76.
    Tennant, F. S., Russell, B. A., Casas, S. K., & Bleich, R. N. Heroin detoxification: A comparison of propoxsyphene and methadone. Journal of the American Medical Association 232:1019–1022, 1975.PubMedGoogle Scholar
  77. 77.
    Jasinski, D. R., Pevnick, J. S., Clark, S. C., & Griffith, J. D. Therapeutic usefulness of propoxyphene nap-sylate in narcotic addiction. Archives of General Psychiatry 34:227–233, 1977.PubMedGoogle Scholar
  78. 78.
    Ives, T. J., & Stults, C. C. Short-course diphenoxylate hydrochloride for treatment of methadone withdrawal symptoms. British Journal of Psychiatry 143:513–514, 1983.PubMedGoogle Scholar
  79. 79.
    Gossop, M., & Strang, J. A comparison of the withdrawal responses of heroin and methadone addicts during detoxification. British Journal of Psychiatry 158:697–699, 1991.PubMedGoogle Scholar
  80. 80.
    Tennant, F. S., & Uelman, G. F. Prescribing narcotics to habitual and addicted narcotic users. Medical and legal guidelines in California and some other Western States. Western Journal of Medicine 133:539–545, 1980.PubMedGoogle Scholar
  81. 81.
    Rosen, M. I., McMahon, T. J., Hameedi, F. A., et al. Effect of Clonidine pretreatment on naloxone-precipitated opiate withdrawal. Journal of Pharmacology and Experimental Therapeutics 276:1128–1135, 1996.PubMedGoogle Scholar
  82. 82.
    O’Connor, P. G., Carroll, K. M., Shi, J. M., et al. Three methods of opioid detoxification in a primary care setting: A randomized trial. Annals of Internal Medicine 127:526–530, 1997.PubMedGoogle Scholar
  83. 83.
    McCann, M. J., Miotto, K., Rawson, R. A., et al. Outpatient non-opioid detoxification for opioid withdrawal: Who is likely to benefit? American Journal of Addiction 6:218–223, 1997.Google Scholar
  84. 84.
    Rasmussen, K., Kendrick, W. T., Kogan, J. H., &Aghajanian, G. K. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology 15:497–505, 1996.PubMedGoogle Scholar
  85. 85.
    Charney, D. S., Heninger, G. R., & Kleber, H. D. The combined use of Clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. American Journal of Psychiatry 143:831–837, 1986.PubMedGoogle Scholar
  86. 86.
    San, L., Camí, J., Peri, J. M., et al. Efficacy of Clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: A controlled clinical trial. British Journal of Addiction 85:141–147, 1990.PubMedGoogle Scholar
  87. 87.
    Hartmann, F., Poirier, M.-R., Bourdel, M.-C., et al. Comparison of acetorphan with Clonidine for opiate withdrawal symptoms. American Journal of Psychiatry 148:627–629, 1991.PubMedGoogle Scholar
  88. 88.
    Lauzon, P., Bruneau, J., Remondin, M., et al. A comparison of Clonidine and methadone in heroin withdrawal in a hospital setting. Psychotropes 4:45–56, 1996.Google Scholar
  89. 89.
    Kleber, H. D., Topazian, M., Gaspari, J., et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. American Journal of Drug and Alcohol Abuse 13:1–17, 1987.PubMedGoogle Scholar
  90. 90.
    O’Connor, P. G., & Kosten, T. R. Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association 279:229–234, 1998.PubMedGoogle Scholar
  91. 91.
    Bartter, T., & Gooberman, L. L. Rapid opiate detoxification. American Journal of Drug and Alcohol Abuse 22:489–495, 1996.PubMedGoogle Scholar
  92. 92.
    Hall, W., Mattick, R. P., Saunders, J. B., & Wodak, A. Rapid opiate detoxification treatment. Drug and Alcohol Review 16:325–327, 1997.PubMedGoogle Scholar
  93. 93.
    Clark, H. W., & Longmuir, N. Clonidine transdermal patches: A recovery-oriented treatment of opiate withdrawal. Newsletter: California Society for the Treatment of Alcoholism and Other Drug Dependencies 13, 1986.Google Scholar
  94. 94.
    Gariti, P., Auriacombe, M., Incmikoski, R., et al. A randomized double-blind study of neuroelectric therapy in opiate and cocaine detoxification. Journal of Substance Abuse 4:299–308, 1992.PubMedGoogle Scholar
  95. 95.
    Smith, M. O., Brewington, V., Culliton, P., et al. Acupuncture. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 484–492.Google Scholar
  96. 96.
    Hutchings, D. E. Opiates during pregnancy: Neurobehavioral effects in the offspring. Biological Psychiatry 31.195A, 1992.Google Scholar
  97. 97.
    Finnegan, L. P., & Kandall, S. R. Maternal and neonatal effects of alcohol and drugs. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 513–534.Google Scholar
  98. 98.
    Hoder, E. L., Leckman, J. F., Ehrenkranz, R., et al. Clonidine in neonatal narcotic-abstinence syndrome. New England Journal of Medicine 305:1284, 1981.PubMedGoogle Scholar
  99. 99.
    Hulse, G. K., Milne, E., English, D. R., & Holman, C. D. The relationship between maternal use of heroin and methadone and infarct birth weight. Addiction 92:1571–1579, 1997.PubMedGoogle Scholar
  100. 100.
    Hulse, G. K., Milne, E., English, D. R., & Holman, C. D. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 93:1033–1042, 1998.PubMedGoogle Scholar
  101. 101.
    Strass, M. E., Andresko, M., Stryker, J. C., & Wardell, J. N. Relationship of neonatal withdrawal to maternal methadone dose. American Journal of Drug and Alcohol Abuse 3:339–345, 1976.Google Scholar
  102. 102.
    Finnegan, L. P. Neonatal abstinence syndrome: Assessment and pharmacotherapy. In F. F. Rubaltelli & B. Granati (Eds.), Neonatal therapy: An update. New York: Elsevier, 1986, pp. 122–146.Google Scholar
  103. 103.
    Eisendrath, S. J., Goldman, B., Douglas, J., et al. Meperidine-induced delirium. American Journal of Psychiatry 144:1062–1065, 1987.PubMedGoogle Scholar
  104. 104.
    Rogers, R. D., Everitt, B. J., Baldacchino, A., et al. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and trypto-phan-depleted normal volunteers: Evidence for monoaminergic mechanisms. Neuropsychopharmacology 20:322–339, 1999.PubMedGoogle Scholar
  105. 105.
    Oppenheimer, E., Stimson, G. V., & Thorley, A. Seven-year follow-up of heroin addicts: Abstinence and continued use compared. British Medical Journal 2:627–630, 1979.PubMedGoogle Scholar
  106. 106.
    Goodwin, D. W., & Guze, S. B. (Eds.), Psychiatric diagnosis (5th ed.). New York: Oxford University Press, 1996.Google Scholar
  107. 107.
    The Medical Letter on Drugs and Therapeutics. Some drugs that cause psychiatric symptoms. The Medical Letter Inc. New Rochelle, NY, 1998, pp. 21–24.Google Scholar
  108. 108.
    Kosten, T. R., Rounsaville, B. J., & Kleber, H. D. A 2.5 year follow-up of depression among opiate addicts. Archives of General Psychiatry 43:733–738, 1986.PubMedGoogle Scholar
  109. 109.
    Kosten, T. R., & Rounsaville, B. J. Suicidality among opioid addicts. American Journal of Drug and Alcohol Abuse 14:357–369, 1988.PubMedGoogle Scholar
  110. 110.
    Handelsman, L., Aronson, M. J., Ness, R., et al. The dysphoria of heroin addiction. American Journal of Drug and Alcohol Abuse 18:275–287, 1992.PubMedGoogle Scholar
  111. 111.
    del Campo, A. F. M., McMurray, R. G., Besser, G. M., & Grossman, A. Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers. Biological Psychiatry 32:344–353, 1992.Google Scholar
  112. 112.
    Kanof, P. D., Aronson, M. J., & Ness, R. Organic mood syndrome associated with detoxification from methadone maintenance. American Journal of Psychiatry 150:423–428, 1993.PubMedGoogle Scholar
  113. 113.
    Brooner, R. K., King, V. L., Kidorf, M., et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry 54:71–80, 1997.PubMedGoogle Scholar
  114. 114.
    Passaro, D. J., Werner, S. B., McGee, J., et al. Wound botulism associated with black tar heroin among injecting drug users. Journal of the American Medical Association 279:859–863, 1998.PubMedGoogle Scholar
  115. 115.
    Metzger, D. S., Woody, G. E., McLellan, A. T., et al. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month, prospective follow-up. Journal of Acquired Immunodeficiency 6:1049–1056, 1993.Google Scholar
  116. 116.
    Metzger, D., Woody, G., De Philippis, D., et al. Risk factors for needle sharing among methadone-treated patients. American Journal of Psychiatry 145:636–640, 1991.Google Scholar
  117. 117.
    Dinwiddie, S. H., Reich, T., & Cloninger, C. R. Lifetime complications of drug use in intravenous drug users. Journal of Substance Abuse 4:13–18, 1992.PubMedGoogle Scholar
  118. 118.
    Gostin, L. O., Lazzarini, Z., Jones, T. S., & Flaherty, K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. Journal of the American Medical Association 277:53–62, 1997.PubMedGoogle Scholar
  119. 119.
    Strathdee, S. A., Patrick, D. M., Archibald, C. P., et al. Social determinants predict needle-sharing behavior among injection drug users in Vancouver, Canada. Addiction 92:1139–1347, 1997.Google Scholar
  120. 120.
    Shafer, D. A., Falek, A., Donahoe, R. M., & Madden, J. J. Biogenetic effects of opiates. International Journal of Addiction 25:1–18, 1991.Google Scholar
  121. 121.
    Lettau, L. A., McCarthy, J. G., Smith, M. J., et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parental drug abusers and their contacts. New England Journal of Medicine 317:1256–1262, 1987.PubMedGoogle Scholar
  122. 122.
    Oliver, R. M. Bronchospasm and heroin inhalation. Lancet 1:915, 1986.PubMedGoogle Scholar
  123. 123.
    Mendelson, J. H., Teoh, K. S., Mello, N. K., & Ellingbone, J. Buprenorphine attenuates the effects of cocaine on adrenocorticotropin (ACTH) secretion and mood states in man. Neuropsychopharmacology 7:157–162, 1992.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Marc A. Schuckit
    • 1
  1. 1.University of California Medical School and Veterans Affairs San Diego Healthcare SystemSan DiegoUSA

Personalised recommendations